Loading...
Loading...
Keryx Biopharmaceuticals, Inc.
, a biopharmaceutical company focused on bringing innovative
therapies to market for patients with renal disease, today announced the
publication of Auryxia phase 2 clinical trial results in non-dialysis
dependent chronic kidney disease (NDD-CKD) patients in the American Journal of
Kidney Diseases (AJKD). Based on the results of this study, in September 2014,
the Company initiated a Phase 3 pivotal program of Auryxia as a treatment for
iron-deficiency anemia in patients with Stages 3-5 NDD-CKD.
The study's Co-Chairmen were Geoffrey Block, MD, Director of Clinical Research
at Denver Nephrology; Glenn Chertow, MD, Professor of Medicine and Chief,
Division of Nephrology at Stanford University School of Medicine; and Steven
Fishbane, MD, Division Chief, Kidney Disease and Hypertension at North Shore
University Hospital/Long Island Jewish Medical Center.
Dr. Block commented, "Iron deficiency anemia is very common in chronic kidney
disease stages 3 to 5, with more than 1.5 million Americans estimated to be
impacted by this condition. Currently, there are no good treatment options for
patients as conventional oral iron formulations are poorly absorbed and not
well tolerated. The results of this study support further evaluation of
Auryxia for the treatment of iron deficiency anemia in this patient
population."
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in